Zacks: Brokerages Anticipate CryoPort Inc (NASDAQ:CYRX) Will Post Quarterly Sales of $7.82 Million

Share on StockTwits

Wall Street analysts expect CryoPort Inc (NASDAQ:CYRX) to post $7.82 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for CryoPort’s earnings. The highest sales estimate is $8.10 million and the lowest is $7.40 million. CryoPort reported sales of $4.63 million during the same quarter last year, which indicates a positive year over year growth rate of 68.9%. The company is scheduled to announce its next quarterly earnings results on Thursday, August 8th.

On average, analysts expect that CryoPort will report full year sales of $33.76 million for the current financial year, with estimates ranging from $32.00 million to $35.69 million. For the next fiscal year, analysts forecast that the company will post sales of $50.88 million, with estimates ranging from $47.00 million to $58.53 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover CryoPort.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings data on Thursday, May 2nd. The consumer goods maker reported ($0.08) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.08). CryoPort had a negative return on equity of 28.30% and a negative net margin of 41.61%. The business had revenue of $6.65 million for the quarter, compared to the consensus estimate of $6.56 million. During the same quarter in the previous year, the company posted ($0.10) EPS. The company’s revenue was up 65.4% compared to the same quarter last year.

A number of equities analysts have recently commented on CYRX shares. BidaskClub upgraded Zebra Technologies from a “hold” rating to a “buy” rating in a report on Saturday, July 6th. Needham & Company LLC reiterated a “buy” rating and issued a $40.00 target price on shares of ACADIA Pharmaceuticals in a report on Monday, July 1st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. CryoPort has a consensus rating of “Buy” and a consensus target price of $20.00.

Several institutional investors have recently made changes to their positions in CYRX. BNP Paribas Arbitrage SA purchased a new position in shares of CryoPort in the 1st quarter worth approximately $74,000. Metropolitan Life Insurance Co. NY boosted its holdings in CryoPort by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,607 shares of the consumer goods maker’s stock valued at $95,000 after acquiring an additional 6,722 shares during the period. MML Investors Services LLC purchased a new position in CryoPort during the 4th quarter valued at $157,000. Bank of America Corp DE boosted its holdings in CryoPort by 92.3% during the 4th quarter. Bank of America Corp DE now owns 16,037 shares of the consumer goods maker’s stock valued at $176,000 after acquiring an additional 7,697 shares during the period. Finally, Conestoga Capital Advisors LLC purchased a new position in CryoPort during the 1st quarter valued at $355,000. Hedge funds and other institutional investors own 52.53% of the company’s stock.

Shares of CryoPort stock traded up $0.12 on Friday, reaching $19.71. The company had a trading volume of 226,536 shares, compared to its average volume of 394,760. The firm has a market capitalization of $608.55 million, a price-to-earnings ratio of -63.58 and a beta of 0.85. The company has a current ratio of 11.57, a quick ratio of 11.52 and a debt-to-equity ratio of 0.42. The firm’s 50-day simple moving average is $18.15. CryoPort has a 1 year low of $8.28 and a 1 year high of $20.20.

CryoPort Company Profile

CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.

Read More: The primary rules of Elliott Wave theory

Get a free copy of the Zacks research report on CryoPort (CYRX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for CryoPort (NASDAQ:CYRX)

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with's FREE daily email newsletter.